Published: 2021-11-26

Chronic myeloid leukemia on imatinib with recurrent sub-dural haemorrhage

Ambati Bhavani, Palanki Satya Dattatreya, Vinukonda Shyamala


Imatinib is an FDA approved first-line treatment for Philadelphia-positive CML. It is a selective tyrosine kinase inhibitor specifically targeting BCR-ABL, c-KIT, PDGFRA. It has been reported with low incidence of adverse effects and high tolerability, with haemorrhagic events being a rare complication. We report here a case of 51-year-old female patient with chronic myeloid leukemia who was on high dose imatinib experienced recurrent sub-dural haemorrhage. This case report emphasizes on the need to consider Sub dural haemorrhage as an unusual cause of headache associated with vomiting in a patient taking high dose of imatinib.


Chronic myeloid leukemia, Imatinib, Subdural hemorrhage

Full Text:



Nash I. Chronic myeloid leukemia. N Engl J Med. 1999;341:765.

O'Brien SG, Guilhot F, Larson RA. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.

Chen JC, Levy ML. Causes, epidemiology, and risk factors of chronic subdural hematoma. Neurosur clin North Am. 2000;11(3):399-406.

Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. Chronic myelogenous leukemia. ASH Education Program Book. 2001;2001(1):87-112.

Song KW, Rifkind J, Al-Beirouti B. Subdural hematomas during CML therapy with imatinib mesylate. Leuk Lymphoma. 2004;45:1633-6.

Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114:261-3.

Matsue K, Aoki T, Odawara J, Kimura S, Yamakura M, Takeuchi M. Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia. Leuk Res. 2009;33:867-9.

Okajima K, Kohno I, Tsuruta J, Okabe H, Takatsuki K, Binder BR. Direct evidence for systemic fibrinogenolysis in a patient with metastatic prostatic cancer. Thromb Res. 1992;66:717-27.

Kluft C, Vellenga E, Brommer EJ, Wijngaards G. A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. Blood. 1982;59:1169-80.

Favier R, Aoki N, de Moerloose P. Congenital alpha (2)-plasmin inhibitor deficiencies: a review. Br J Haematol. 2001;114:4-10.